The Recall Desk

State

Georgia product recalls

73,833 recalls have nationwide distribution and so reach Georgia. 9,635 additional recalls listed Georgia specifically in their distribution scope.

What the numbers show

Total
9,635
Critical
1,471
Severe
2,567
Most recent
2026-11-04

Of the 9,635 recalls naming Georgia we have scored against our rubric, 1,471 (15%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 2,567 (27%) are Severe.

These figures cover only the 9,635 recalls whose distribution notice names Georgia specifically. The 73,833 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

62326–62350 of 83468

  • SevereFDA (Drugs)·D-800-2015·2015-04-29

    Attix Pharmaceuticals Recalls Minoxidil API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Minoxidil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Minoxidil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-870-2015·2015-04-29

    Attix Pharmaceuticals Recalls Proparacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Proparacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Proparacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-941-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trehalose Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trehalose Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trehalose Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-593-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clindamycin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clindamycin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clindamycin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-565-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carvedilol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carvedilol active pharmaceutical ingredient because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.

    Product
    Carvedilol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-667-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etravirine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etravirine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Etravirine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-798-2015·2015-04-29

    Miltefosine API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Miltefosine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Miltefosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-715-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrocortisone Micronized Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydrocortisone Micronized active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydrocortisone Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-730-2015·2015-04-29

    Attix Pharmaceuticals Recalls Imatinib Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Imatinib Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Imatinib Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-910-2015·2015-04-29

    Tacrolimus Monohydrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tacrolimus Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tacrolimus Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-697-2015·2015-04-29

    Attix Pharmaceuticals Recalls Gatifloxacin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Gatifloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Gatifloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-872-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pyridostigmine Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pyridostigmine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pyridostigmine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-815-2015·2015-04-29

    Attix Pharmaceuticals Recalls Neostigmine Methylsulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Neostigmine Methylsulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Neostigmine Methylsulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-712-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrochlorothiazide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydrochlorothiazide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydrochlorothiazide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-788-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methscopolamine Bromide Combo active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-638-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dopamine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dopamine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dopamine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-725-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyoscine Butylbromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hyoscine Butylbromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hyoscine Butylbromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-554-2015·2015-04-29

    Cabergoline API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Cabergoline active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cabergoline active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-763-2015·2015-04-29

    Lincomycin HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Lincomycin HCl Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Lincomycin HCl Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-530-2015·2015-04-29

    Avanafil API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling all lots of Avanafil active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Avanafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-575-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloramphenicol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloramphenicol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Chloramphenicol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-517-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amlodipine Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Amlodipine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amlodipine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-698-2015·2015-04-29

    Gefitinib API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Gefitinib active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Gefitinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-572-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cephalexin Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cephalexin Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cephalexin Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-837-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pergolide Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pergolide Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pergolide Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide